Skip to main content
SpringerLink
Log in

Human Haemoglobin — Hemosol

Hemolink

  • Adis R&D Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Cheng D, Martineau R, MacAdams C, et al. Safety of Hemolink™ as an oxygen therapeutic in patients undergoing coronary artery bypass graft surgery. Anesth Analg 2001 Apr; 92: 3

    Google Scholar 

  2. Hill SE, Gottschalk L, Chelly J, et al. Safety and efficacy of O-raffinose cross-linked human hemoglobin in patients undergoing coronary bypass grafting. Anesth Analg 2001 Apr; 92: 4

    Google Scholar 

  3. . Hemosol’s blood substitute, Hemolink (Rm) cleared by FDA for US phase II trials for treatment of chronic anemia. PR Newswire [online]. Available from URL: http://www.newspage.com [Accessed 1998 May 4]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Human Haemoglobin — Hemosol. BioDrugs 16, 223–225 (2002). https://doi.org/10.2165/00063030-200216030-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200216030-00009

Search

Navigation